LBCL continues to present major clinical challenges despite improvements with chemoimmunotherapy. Credit: SVStocker via Shutterstock. At the European Society for Medical Oncology (ESMO) Congress, held ...
Please provide your email address to receive an email when new articles are posted on . Tandem-target CAR-T produced a response in all participants with relapsed or refractory mantle cell lymphoma in ...
Glioblastoma (GBM) is an aggressive and common brain cancer in adults with average life expectancies of 12–18 months after diagnosis and median survival rate for recurrent GBM ranging from 6–10 months ...
Hosted on MSN
CIDP study explores dual-target CAR-T cell therapy for the treatment of relapsed/refractory autoimmune disorders
Chinese scientists reveal the feasibility, tolerability, and efficacy of BCMA-CD19 bispecific CAR T-cells for treating chronic inflammatory demyelinating polyneuropathy (CIDP) and highlight the ...
Hosted on MSN
Miltenyi Biotec's ZAMTO Cell, claimed to be India's first dual-target CAR-T cancer therapy, expected by 2026
German biotechnology company Miltenyi Biotec has said that its CAR-T therapy, ZAMTO Cell, for B-cell lymphoma, is expected to be available in India by early 2026. CAR-T (Chimeric Antigen Receptor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results